Drugs / RBM-007
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04895293 | Jun 2021 → Feb 2022 | age-related macular degeneration | Maturi, Raj K., M.D., P.C. | Completed | No outcome recorded |
| Phase 1/2 | NCT03633084 | Aug 2018 → Jun 2019 | age-related macular degeneration | Ribomic USA Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04640272 | Nov 2020 → Nov 2021 | wet macular degeneration | Ribomic USA Inc | Completed | No outcome recorded |
| Phase 2 | NCT04200248 | Dec 2019 → Nov 2021 | wet macular degeneration | Ribomic USA Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBM-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04200248 ↗ |
| Action | Inhibit | “potent anti-FGF2 activity and anti-VEGF-expression activity” NCT04200248 ↗ |
| Modality | Aptamer | “novel oligonucleotide-based aptamer” NCT04200248 ↗ |
| Route | Intravitreal | “single intravitreal (i.vt.) injection” NCT03633084 ↗ |